Omacor (Omega-3-Acid Ethyl Esters 90)

After oral ingestion, Omega-3-acid ethyl esters are converted to EPA and DHA, which inhibit hepatic VLDL synthesis, increase fatty‑acid beta‑oxidation, and reduce the activity of enzymes involved in triglyceride production. These actions collectively lower circulating triglyceride concentrations.

The exact dose of Omacor is individualized by the prescribing clinician based on the patient’s triglyceride level, response to therapy, and overall clinical profile. Dosage decisions consider factors such as baseline lipid values, concomitant medications, and any existing comorbidities.

Omacor should be used during pregnancy or lactation only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Health professionals typically evaluate the risk‑benefit ratio on a case‑by‑case basis and may consider alternative lipid‑lowering strategies when appropriate.

To place an order, submit an enquiry on the Omacor product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Omacur contains prescription‑strength omega‑3‑acid ethyl esters, delivering higher EPA/DHA concentrations than most over‑the‑counter fish‑oil supplements. This higher potency enables more reliable triglyceride reduction, but it also requires medical supervision and monitoring for potential interactions and adverse effects.

Omacor should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keeping the product in a stable environment helps maintain its potency and prevents degradation of the ethyl‑ester formulation.

Omacor is taken orally, usually with meals to improve tolerability and absorption. The capsules are swallowed whole with water; they should not be opened, crushed, or mixed with other substances unless specifically instructed by a healthcare professional.

The most serious risks include pancreatitis, severe allergic reactions (such as anaphylaxis), significant bleeding events—especially when combined with anticoagulants—and hepatic injury indicated by elevated liver enzymes. Patients should be monitored regularly for these potential complications.

Omacor is contraindicated in patients with known hypersensitivity to omega‑3 fatty acids or any capsule excipients. It should also be avoided in individuals with active bleeding disorders, severe liver disease, or those who are currently taking high‑dose omega‑3 supplements without medical supervision.